Cytokinetics (NASDAQ:CYTK) is scheduled to announce its earnings results on Wednesday, February 14th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Shares of Cytokinetics (NASDAQ:CYTK) opened at $8.60 on Tuesday. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14. Cytokinetics has a fifty-two week low of $7.00 and a fifty-two week high of $17.20. The firm has a market capitalization of $463.41, a price-to-earnings ratio of -5.18 and a beta of 1.03.

Several equities research analysts recently weighed in on CYTK shares. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Cytokinetics in a report on Friday, October 27th. Needham & Company LLC downgraded Cytokinetics from a “strong-buy” rating to a “buy” rating and decreased their price target for the stock from $22.00 to $12.00 in a report on Wednesday, November 29th. TheStreet downgraded Cytokinetics from a “c” rating to a “d” rating in a report on Friday, October 27th. Cantor Fitzgerald reissued a “hold” rating and issued a $10.00 target price on shares of Cytokinetics in a report on Wednesday, January 17th. Finally, JMP Securities reissued an “outperform” rating and issued a $13.00 target price (down previously from $17.00) on shares of Cytokinetics in a report on Tuesday, November 21st. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $17.91.

WARNING: This piece was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://theolympiareport.com/2018/02/13/cytokinetics-cytk-scheduled-to-post-quarterly-earnings-on-wednesday.html.

About Cytokinetics

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Earnings History for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.